Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCPH 
Scpharmaceuticals Inc (SCPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/06/2025: SCPH (3-star) is a STRONG-BUY. BUY since 26 days. Simulated Profits (3.09%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.21% | Avg. Invested days 29 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 304.36M USD | Price to earnings Ratio - | 1Y Target Price 5.67 |
Price to earnings Ratio - | 1Y Target Price 5.67 | ||
Volume (30-day avg) 6 | Beta 0.3 | 52 Weeks Range 1.94 - 6.28 | Updated Date 10/15/2025 |
52 Weeks Range 1.94 - 6.28 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -183.55% | Operating Margin (TTM) -89.11% |
Management Effectiveness
Return on Assets (TTM) -57.08% | Return on Equity (TTM) -934.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 315460991 | Price to Sales(TTM) 6.09 |
Enterprise Value 315460991 | Price to Sales(TTM) 6.09 | ||
Enterprise Value to Revenue 6.31 | Enterprise Value to EBITDA -6.69 | Shares Outstanding 53678797 | Shares Floating 32715560 |
Shares Outstanding 53678797 | Shares Floating 32715560 | ||
Percent Insiders 5.98 | Percent Institutions 80.35 |
Upturn AI SWOT
Scpharmaceuticals Inc
Company Overview
History and Background
Scpharmaceuticals Inc. (SCPH) is a pharmaceutical company focused on developing and commercializing products that address critical care and hospital-based therapeutic needs. Founded in 1998, the company has evolved through various stages of research, development, and commercialization of its proprietary therapies.
Core Business Areas
- Hospital Therapeutics: Focuses on developing and commercializing products for acute care settings, particularly for conditions like sepsis, acute kidney injury, and other critical illnesses.
Leadership and Structure
The leadership team comprises experienced pharmaceutical executives with expertise in research, development, regulatory affairs, and commercialization. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- DefenCath: DefenCath is a novel antimicrobial catheter lock solution used to prevent catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. The competitors in this market are companies offering alternative catheter lock solutions or antimicrobial strategies. Market share of DefenCath is growing as hospitals adopt its use.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant R&D investments. The acute care segment is driven by the increasing prevalence of hospital-acquired infections and the need for innovative therapies.
Positioning
Scpharmaceuticals Inc. is positioning itself as a leader in developing and commercializing innovative therapies for critical care. Its competitive advantage lies in its proprietary technology platform and focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for CRBSI prevention is substantial. Scpharmaceuticals Inc. aims to capture a significant portion of this market with DefenCath.
Upturn SWOT Analysis
Strengths
- Novel antimicrobial technology
- Focus on unmet medical needs
- Experienced management team
- FDA-approved product (DefenCath)
Weaknesses
- Reliance on a single product (DefenCath)
- Limited commercial infrastructure
- Potential for generic competition
- Cash burn
Opportunities
- Expansion into new indications
- Strategic partnerships
- Geographic expansion
- Increasing awareness of CRBSIs
Threats
- Regulatory hurdles
- Competition from established players
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BDX
- MLND
Competitive Landscape
Scpharmaceuticals Inc. faces competition from established medical device and pharmaceutical companies. Its competitive advantage lies in its novel antimicrobial technology and focus on unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: The historical growth is characterized by periods of intense research and development, followed by product approvals and commercial launches.
Future Projections: Future growth depends on successful commercialization of DefenCath and potential expansion into new indications.
Recent Initiatives: Recent initiatives include expanding the sales force and marketing efforts for DefenCath, as well as conducting further research and development of its product pipeline.
Summary
Scpharmaceuticals Inc. is a company with a unique antimicrobial product, but faces challenges with revenue and cash flow. DefenCath holds promise, but commercial success is critical for long-term sustainability. The company must manage its debt, reduce costs, and capitalize on future opportunities to demonstrate its viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), investor presentations, news articles, analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scpharmaceuticals Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-11-17 | President, CEO, Principal Executive Officer & Director Mr. John H. Tucker | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | |
Full time employees 162 | |||
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. As of October 7, 2025, scPharmaceuticals Inc. operates as a subsidiary of MannKind Corporation.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.